Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Cash from Operations: 2013-2024

Historic Cash from Operations for Aclaris Therapeutics (ACRS) over the last 12 years, with Dec 2024 value amounting to -$20.1 million.

  • Aclaris Therapeutics' Cash from Operations fell 149.69% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.9 million, marking a year-over-year decrease of 139.80%. This contributed to the annual value of -$20.1 million for FY2024, which is 74.37% up from last year.
  • As of FY2024, Aclaris Therapeutics' Cash from Operations stood at -$20.1 million, which was up 74.37% from -$78.3 million recorded in FY2023.
  • In the past 5 years, Aclaris Therapeutics' Cash from Operations ranged from a high of -$20.1 million in FY2024 and a low of -$78.3 million during FY2023.
  • In the last 3 years, Aclaris Therapeutics' Cash from Operations had a median value of -$67.6 million in 2022 and averaged -$55.3 million.
  • In the last 5 years, Aclaris Therapeutics' Cash from Operations plummeted by 34.95% in 2021 and then soared by 74.37% in 2024.
  • Yearly analysis of 5 years shows Aclaris Therapeutics' Cash from Operations stood at -$38.6 million in 2020, then tumbled by 34.95% to -$52.1 million in 2021, then dropped by 29.60% to -$67.6 million in 2022, then dropped by 15.92% to -$78.3 million in 2023, then soared by 74.37% to -$20.1 million in 2024.